Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
Genenta Science (NASDAQ: GNTA) announced its participation in several scientific congresses in May and June 2022, showcasing advancements in immuno-gene therapy for cancer. Presentations include:
- ASGCT Annual Meeting: May 19 - TEM-GBM study findings.
- Brain Tumor Meeting: May 19-20 - Patient case using Temferon™.
- ASCO Annual Meeting: June 5 - Tumor immune microenvironment research.
- EHA Virtual Congress: June 10 - Gene-modified cells' effects.
Genenta focuses on innovative therapies targeting solid tumors to enhance immune responses.
- None.
- None.
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be presenting at several upcoming scientific congresses in May and June.
Details of the presentations are as follows:
American Society of Cell and Gene Therapy (ASGCT) 25th Annual Meeting, May 16-19, Washington and virtual
Title: Autologous Cell & Gene Therapy for the Therapeutic Targeting of Immune Payloads to the Solid Tumor Microenvironment. Preliminary results of the TEM-GBM study
Type: Oral presentation during the Clinical Trials Spotlight Symposium
Time: May 19, 2022, 8:45 AM – 9:00 AM ET
Brain Tumor Meeting (BTM) 2022, May 19-20, Berlin
Title: Evidence for Interferon alpha mediated disease stabilization in one patient affected by glioblastoma using a novel genetically modified cell therapy (Temferon™)
Type: Poster Presentation
Time: May 19-20, 2022
2022 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, Chicago and virtual
Title: Harnessing genetically engineered hematopoietic progenitor cells to redirect the tumor immune microenvironment against glioblastoma (TEM-GBM Study)
Type: Poster presentation
Time: June 5, 2022, 8:00 AM - 11:00 AM ET
European Hematology Association (EHA) 2022 Virtual Congress, June 9-12, Vienna and virtual
Title: Using Gene-Modified Autologous Stem Cells Progeny to Reeducate the Tumor Immune Microenvironment of Solid Tumors (TEM-GBM Study)
Type: Poster presentation
Time: June 10, 2022, 4:30 PM - 4:45 PM CEST
About Genenta Science
Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is designed to reach solid tumors, induce a durable immune response not restricted to pre-selected tumor antigens nor type, and avoid systemic toxicity, which are some of the main unresolved challenges in immuno-oncology.
Forward-Looking Statements
Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion and timing of the phase 1/2a clinical trial or any studies relating to the treatment of glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM). Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Genenta Science S.p.A. (GNTA) undertakes no duty to update such information except as required under applicable law.
| Investor Relations - LifeSci Advisors: Mary-Ann Chang, CFA +44 7483 28 48 53 mchang@lifesciadvisors.com | Genenta Media Tiziana Pollio +39 3482315143 tiziana.pollio@genenta.com |
FAQ
What is Genenta Science's stock symbol?
When is Genenta Science presenting at the ASGCT Annual Meeting?
What is the focus of Genenta Science's presentation at the Brain Tumor Meeting?
What are the key dates for Genenta Science's presentations in June 2022?
What is Temferon™ and its relevance to Genenta Science?
